Is TLRY a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on International medical cannabis growth, with revenue (ttm) at ~$963M; fiscal Q1 2027 ~$257M, +23% yoy (BrewDog-driven). The bear case rests on the biggest risk is that Tilray remains unprofitable on a net basis and has repeatedly issued new shares, diluting existing holders, a major reason the stock trades at a very low absolute price. Analysts covering it are spread from $4.00 to $12.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. The biggest risk is that Tilray remains unprofitable on a net basis and has repeatedly issued new shares, diluting existing holders, a major reason the stock trades at a very low absolute price. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $4.00, +31.6% from the $3.04 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

International medical cannabis growth. Tilray's fastest-growing engine is international medical cannabis, especially Germany, where 2024 reforms expanded patient access. The most optimistic analyst target on TLRY is $12.00, +294.7% from the $3.04 price. That figure is only reachable if this thesis works close to its best case.

The biggest risk is that Tilray remains unprofitable on a net basis and has repeatedly issued new shares, diluting existing holders, a major reason the stock trades at a very low absolute price. Cannabis legalization, the core long-term catalyst, has stalled in the US and moves slowly elsewhere, so the biggest addressable market may stay closed for years. Cannabis revenue itself fell about 13% year over year in fiscal Q1 2027, operating expenses rose roughly 83%, and quarterly cash burn widened to about $16.5 million, so the core business is not yet carrying its own costs. The Canadian adult-use market is oversupplied and price-competitive, and the craft beer segment faces industry-wide volume softness. Currency swings affect large international sales, and the company relies on acquisitions that carry integration risk. The stock is highly volatile and speculative, sensitive to legalization headlines, and the company explored a reverse stock split to maintain its Nasdaq listing, a reminder of the low share price. The most pessimistic published target is $4.00, +31.6% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Tilray Brands, Inc., a lifestyle consumer products company, engages in the research, cultivation, processing, and distribution of medical cannabis products in Canada, the United States, Europe, the Middle East, Africa.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (International medical cannabis growth) stalling in the reported numbers rather than in the narrative, the risk above (the biggest risk is that Tilray remains unprofitable on a net basis and has repeatedly issued new shares, diluting existing holders, a major reason the stock trades at a very low absolute price) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

That depends on your goals, time horizon, and risk tolerance, and this is not investment advice. The bull case is fast-growing international medical cannabis (especially Germany), a diversified craft-beer business, and upside if US legalization arrives. The bear case is ongoing net losses (about $164 million over the trailing twelve months), shrinking core cannabis revenue, repeated share dilution, a very low share price, and legalization that has stalled for years. Tilray is a speculative, high-volatility stock, so weigh it carefully against your risk tolerance. As of October 16, 2026 the stock was down about 68% year to date.

Tilray is a diversified consumer company operating in four areas: cannabis (medical and adult-use) across Canada, Europe, and beyond; craft beer and beverages through brands like SweetWater, Breckenridge and, since 2026, BrewDog; hemp-based wellness products; and distribution. Unlike pure cannabis names, it earns substantial real revenue from beer and drinks, giving it a foothold in regulated US consumer markets even where cannabis is federally illegal.

No. Tilray does not pay a dividend. As an unprofitable, growth-focused company still investing in cannabis expansion and its beverage business, it reinvests cash rather than returning it to shareholders. Investors hold TLRY for potential capital appreciation tied to revenue growth and cannabis legalization, not for income. Do not expect any payout in the near term.